NCT04311489 - Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Cirrhosis, LiverAscites Hepatic

Interventions

DRUG

Ularitide

Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.

DRUG

Placebo

Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.

Trial Locations (1)

8200

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus